Eurofins CDMO

Executive Summary

Eurofins CDMO is a global contract development and manufacturing organization (CDMO) network offering integrated, end-to-end solutions for preclinical and clinical outsourcing. Specializing in both biologics (including monoclonal antibodies, antibody-drug conjugates, and cell & gene therapies) and small molecules, the company provides drug substance/API and drug product development and manufacturing services. Founded in 2000 and headquartered in Brussels, Belgium, Eurofins CDMO operates a network of facilities worldwide, supporting drug developers from research through clinical stages. The company leverages the broader Eurofins scientific ecosystem to offer quality, speed, and cost efficiency. Despite being privately held and pre-revenue, its established brand and network position it to capture growing CDMO demand driven by increasing pharmaceutical R&D outsourcing and the complexity of biologics manufacturing.

Upcoming Catalysts (preview)

• Q3 2026Expansion of biologics manufacturing capacity in Europe or US to meet rising demand70% success
• Q1 2027Strategic partnership or multi-year supply agreement with a top-20 pharmaceutical company50% success
• Q4 2026Launch of new cell and gene therapy development and manufacturing service platform60% success